Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies

被引：44

作者：

Cooper, LJN

Al-Kadhimi, Z

DiGiusto, D

Kalos , M

Colcher, D

Raubitschek, A

Forman, SJ

Jensen, MC

机构：

[1] City Hope Natl Med Ctr, Beckman Res Inst, Div Mol Med, Duarte, CA 91010 USA

[2] City Hope Natl Med Ctr, Beckman Res Inst, Div Pediat Hematol Oncol, Duarte, CA 91010 USA

[3] City Hope Natl Med Ctr, Beckman Res Inst, Div Hematol & Hematopoiet Cell Transplantat Tran, Duarte, CA 91010 USA

[4] City Hope Natl Med Ctr, Beckman Res Inst, Dept Radioimmunotherapy, Duarte, CA 91010 USA

来源：

BLOOD CELLS MOLECULES AND DISEASES | 2004年 / 33卷 / 01期

关键词：

T cell; leukemia; toxicity;

D O I：

10.1016/j.bcmd.2004.03.003

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The graft-versus-leukemia (GVL)-effect achieved by donor-derived T cells arising from transplanted allogeneic hematopoietic stern cells or given as donor-leukocyte infusions (DLI) after allogeneic transplant, demonstrates that donor-derived T cells can eradicate B-lineage malignancies. However, graft-versus-host-disease (GVHD) occurring after allogeneic hematopoietic stem-cell transplant (HSCT) or polyclonal DLI can limit the efficacy of these interventions. This toxicity can be avoided by using autologous T cells and/or tumor-specific cytotoxic T lymphocytes (CTLs). To generate antigen-specific T cells that can be derived from the allogeneic donor or the patient, we have genetically manipulated T cells to express a CD19-specific chimeric immunoreceptor. This renders T cells specific for CD 19, a cell surface molecule found on B-lineage leukemia and lymphoma. This review will demonstrate the redirected specificity of CD19-specific T cells and implementation of clinical trials using these cellular agents. (C) 2004 Elsevier Inc. All rights reserved.

引用

页码：83 / 89

页数：7

共 52 条

[1] Mechanisms of the graft-versus-leukemia reaction [J].